Grifols, S.a. Class A · BME:GRF
Grifols, S.a. Class A — H1 2017 Earnings Presentation
16 slides from Grifols, S.a. Class A's earnings presentation, Jul 28, 2017
Slide 1: Forward-looking statements disclaimer
The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expres
Slide 2: Divisional sales and adjusted EBITDA highlights
•The Bioscience Division reports an exceptional increase in sales, which grow by 14.4% (10.9% cc1) to reach EUR 1,760 million. •The Diagnostic Division sales increase by 10.8% (7.8% cc) to EUR 351 million. •The Hospital Division grows by 3.0% (1.9% cc), while sales of the Bio Supplies Division incre
Slide 3: R&D investment and portfolio developments
•The company increases its net investments in R&D+i by 19.0% to EUR 129 million. Grifols manages its innovation strategy through both internal and investee projects, such as the recent acquisition of a 44% stake in the U.S. firm GigaGen for USD 35 million. •The group expands its portfolio of plasma
Slide 4: H1 2017 financial results
(1) Excludes non-recurring costs and associated with recent acquisitions (2) Excludes non-recurring costs and associated with recent acquisitions, am ortiz ation of deferred expenses associated to the refinancing and am ortiz ation of intangib le assets related to acquisitions (3) Constant currency
Slide 5: Net revenues by division 1H 2017
% Var 14.4% % Var cc* 10.9% 10.8% 7.8% 3.0% 1.9% 14.6% 11.4% (92.5%) (92.6%) ** Com parab le net revenues considering the reclassification of the b iological products for non-therapeutic use sales that since January of 2017 are reported in the Bio Supplies Division 61H 2017 EARNINGS RESULTS | GRIFOL
Slide 6: Net revenues by region 1H 2017
% Var% Var cc* 15.6%11.6% 3.2%3.8% 8.6%4.3% In thousands of euros US + CANADA EU ROW 1H 2017 1,494,131 338,288 360,028 % of Net Revenues 68.2% 15.4% 16.4% 1H 2016** 1,292,192 327,813 331,640 % of Net Revenues 66.2% 16.8% 17.0% TOTAL 2,192,447 100.0% 1,951,645 100.0% 12.3% 9.0% ** Com parab le consid
Slide 7: 81H
81H 2017 EARNINGS RESULTS | GRIFOLS
Slide 8: 91H
91H 2017 EARNINGS RESULTS | GRIFOLS
Slide 9: 101H
101H 2017 EARNINGS RESULTS | GRIFOLS
Slide 10: 111H
111H 2017 EARNINGS RESULTS | GRIFOLS
Slide 11: 121H
121H 2017 EARNINGS RESULTS | GRIFOLS
Slide 12: Net revenues by division 2Q 2017
% Var 13.7% % Var cc* 10.0% 15.8% 12.5% 5.3% 4.1% 70.9% 65.7% (73.8%) (75.1%) ** Com parab le net revenues considering the reclassification of the b iological products for non-therapeutic use sales that since January of 2017 are reported in the Bio Supplies Division 131H 2017 EARNINGS RESULTS | GRIF
Slide 13: Net revenues by region 2Q 2017
% Var% Var cc* 16.5%12.1% 6.9%7.4% 10.7%6.3% In thousands of euros US + CANADA EU ROW 2Q 2017 765,561 176,541 188,665 % of Net Revenues 67.7% 15.6% 16.7% 2Q 2016 ** 657,219 165,105 170,388 % of Net Revenues 66.2% 16.6% 17.2% TOTAL 1,130,767 100.0% 992,712 100.0% 13.9% 10.3% ** Com parab le consideri
Slide 14: Grifols' daily share price, Class A & Class B vs IBEX
GRIFOLS’ DAILY SHARE PRICE, CLASS A & CLASS B vs IBEX 35 Base 100: from December 31, 2016 to June 30, 2017 Source: Infobolsa 150 Class A: +29,2% Class B: +21,7% 140 130 120 110 IBEX-35: +11,7% 100 90 Dec-16Jan-17Feb-17Mar-17Apr-17May-17Jun-17 151H 2017 EARNINGS RESULTS | GRIFOLS
Slide 15: Share performance - 1H 2017
Share performance - 1H 2017 GRIFOLS’ DAILY SHARE PRICE, CLASS A & CLASS B vs IBEX 35 Base 100: from December 31, 2016 to June 30, 2017 Source: Infobolsa 460. Class A: +29,2% Class B: +21,7% 140 130 120 110 + IBEX-35: +11,7% 100 Deo-16 Jani7 Febi7 Mar-17 Apet7 May-17 un-t7 GRIFOLS
Slide 16: Condensed Consolidated Interim Financial Statements June 2017
Condensed Consolidated Interim Financial Statements 30 June 2017 Interim Consolidated Directors’ Report 30 June 2017 (With Limited Review Report thereon) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.) Table of Contents